Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sun Pharma | BSE | Healthcare | Pharmaceuticals | ₹4.16T | 36.3x | 1.28 | ₹1,730 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Sun Pharma | NSE | Healthcare | Pharmaceuticals | ₹4.16T | 36.3x | 1.28 | ₹1,732.25 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Divi's Labs | BSE | Healthcare | Pharmaceuticals | ₹1.58T | 76.5x | 1.6 | ₹5,955 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Divi's Labs | NSE | Healthcare | Pharmaceuticals | ₹1.58T | 76.5x | 1.6 | ₹5,939.50 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.7% Downside | Upgrade to Pro+ | |
Cipla | BSE | Healthcare | Pharmaceuticals | ₹1.17T | 23.5x | 0.69 | ₹1,453.30 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Cipla | NSE | Healthcare | Pharmaceuticals | ₹1.17T | 23.5x | 0.69 | ₹1,453.90 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
Torrent Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.08T | 57.9x | 2.41 | ₹3,184.70 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Torrent Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.08T | 57.9x | 2.41 | ₹3,184 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.9% Upside | Upgrade to Pro+ | |
Mankind Pharma | BSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.83 | ₹2,463.95 | -2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Mankind Pharma | NSE | Healthcare | Pharmaceuticals | ₹1.04T | 48.3x | 2.83 | ₹2,478.45 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | BSE | Healthcare | Pharmaceuticals | ₹1.02T | 18.9x | 7.2 | ₹1,221.60 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Dr Reddy’s Laboratories | NSE | Healthcare | Pharmaceuticals | ₹1.02T | 18.9x | 7.2 | ₹1,221.30 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.6% Upside | Upgrade to Pro+ | |
Lupin | NSE | Healthcare | Pharmaceuticals | ₹981.23B | 37.3x | 0.39 | ₹2,150 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.2% Upside | Upgrade to Pro+ | |
Lupin | BSE | Healthcare | Pharmaceuticals | ₹981.21B | 37.3x | 0.39 | ₹2,156.20 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.4% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | NSE | Healthcare | Pharmaceuticals | ₹966.44B | 21.3x | 0.41 | ₹960.50 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Zydus Lifesciences | BSE | Healthcare | Pharmaceuticals | ₹966.24B | 21.3x | 0.41 | ₹960.15 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.6% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | BSE | Healthcare | Pharmaceuticals | ₹683.02B | 19.6x | 0.74 | ₹1,171.60 | -1.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.1% Upside | Upgrade to Pro+ | |
Aurobindo Pharma | NSE | Healthcare | Pharmaceuticals | ₹682.94B | 19.6x | 0.74 | ₹1,174.75 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32% Upside | Upgrade to Pro+ | |
Abbott India | NSE | Healthcare | Pharmaceuticals | ₹627.63B | 47x | 2.88 | ₹29,528.75 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Abbott India | BSE | Healthcare | Pharmaceuticals | ₹625.25B | 47x | 2.88 | ₹29,491.55 | -1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd | NSE | Healthcare | Pharmaceuticals | ₹574.16B | 26.7x | 0.78 | ₹4,802.70 | -6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
Alkem Laboratories Ltd BO | BSE | Healthcare | Pharmaceuticals | ₹573.63B | 26.7x | 0.78 | ₹4,790 | -7.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.3% Upside | Upgrade to Pro+ | |
Glenmark Pharma | BSE | Healthcare | Pharmaceuticals | ₹429.67B | -49.1x | 0.05 | ₹1,521.15 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Glenmark Pharma | NSE | Healthcare | Pharmaceuticals | ₹429.36B | -49.1x | 0.05 | ₹1,515.65 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.5% Upside | Upgrade to Pro+ | |
Ipca Laboratories | BSE | Healthcare | Pharmaceuticals | ₹367.14B | 55.6x | 1.69 | ₹1,446.10 | -4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
Ipca Laboratories | NSE | Healthcare | Pharmaceuticals | ₹366.74B | 55.6x | 1.69 | ₹1,443.25 | -4.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.6% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | BSE | Healthcare | Pharmaceuticals | ₹362.05B | 53.6x | 8.9 | ₹2,140.75 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.9% Upside | Upgrade to Pro+ | |
GlaxoSmithkline Pharma | NSE | Healthcare | Pharmaceuticals | ₹361.68B | 53.6x | 8.9 | ₹2,135.95 | -3.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.6% Upside | Upgrade to Pro+ | |
Laurus Labs | NSE | Healthcare | Pharmaceuticals | ₹336.17B | 168.1x | 26.1 | ₹623.05 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Laurus Labs | BSE | Healthcare | Pharmaceuticals | ₹335.63B | 168.1x | 26.1 | ₹622.95 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -21.3% Downside | Upgrade to Pro+ | |
Ajanta Pharma Ltd-BO | BSE | Healthcare | Pharmaceuticals | ₹325.10B | 36.3x | 1.62 | ₹2,618.15 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.1% Upside | Upgrade to Pro+ | |
Ajanta Pharma Ltd | NSE | Healthcare | Pharmaceuticals | ₹324.08B | 36.3x | 1.62 | ₹2,594 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20% Upside | Upgrade to Pro+ | |
Piramal Pharma | BSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.73 | ₹219.50 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.8% Upside | Upgrade to Pro+ | |
Piramal Pharma | NSE | Healthcare | Pharmaceuticals | ₹300.23B | 784.4x | 3.73 | ₹220.45 | -2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.9% Upside | Upgrade to Pro+ | |
Suven Pharma | BSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.77 | ₹1,115.95 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.2% Upside | Upgrade to Pro+ | |
Suven Pharma | NSE | Healthcare | Pharmaceuticals | ₹294.70B | 111.3x | -2.77 | ₹1,117.15 | -3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
J.B. Chemicals&Pharma | BSE | Healthcare | Pharmaceuticals | ₹261.26B | 40.7x | 1.75 | ₹1,673 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.1% Upside | Upgrade to Pro+ | |
J.B. Chemicals&Pharma | NSE | Healthcare | Pharmaceuticals | ₹261.25B | 40.7x | 1.75 | ₹1,680.40 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.2% Upside | Upgrade to Pro+ | |
Gland | BSE | Healthcare | Pharmaceuticals | ₹249.86B | 35.4x | 5.13 | ₹1,484.85 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2.1% Upside | Upgrade to Pro+ | |
Gland | NSE | Healthcare | Pharmaceuticals | ₹249.86B | 35.4x | 5.13 | ₹1,481.05 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 2% Upside | Upgrade to Pro+ | |
Wockhardt | NSE | Healthcare | Pharmaceuticals | ₹247.45B | -121.8x | -2.01 | ₹1,520.80 | -4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Wockhardt | BSE | Healthcare | Pharmaceuticals | ₹247.35B | -121.8x | -2.01 | ₹1,522.40 | -5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Concord Biotech | BSE | Healthcare | Pharmaceuticals | ₹245.39B | 60.6x | 9.61 | ₹2,400 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.6% Downside | Upgrade to Pro+ | |
Concord Biotech | NSE | Healthcare | Pharmaceuticals | ₹245.39B | 60.6x | 9.61 | ₹2,275.65 | -3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -6.8% Downside | Upgrade to Pro+ | |
Natco Pharma | NSE | Healthcare | Pharmaceuticals | ₹230.89B | 11.9x | 0.16 | ₹1,287.95 | -2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
Natco Pharma | BSE | Healthcare | Pharmaceuticals | ₹230.66B | 11.9x | 0.16 | ₹1,287.90 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.9% Upside | Upgrade to Pro+ | |
Emcure Pharmaceuticals | BSE | Healthcare | Pharmaceuticals | ₹229.73B | 36.9x | 3.76 | ₹1,172.05 | -3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.1% Upside | Upgrade to Pro+ | |
Emcure Pharmaceuticals | NSE | Healthcare | Pharmaceuticals | ₹229.73B | 36.9x | 3.76 | ₹1,175.30 | -3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.2% Upside | Upgrade to Pro+ | |
Pfizer Ltd | NSE | Healthcare | Pharmaceuticals | ₹194.34B | 31.5x | 1.44 | ₹4,249.50 | -2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.3% Upside | Upgrade to Pro+ | |
Pfizer Ltd | BSE | Healthcare | Pharmaceuticals | ₹193.99B | 31.5x | 1.44 | ₹4,236.90 | -2.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ |